PAPOLG

Across TCGA pan-cancer cohorts, PAPOLG mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated PAPOLG data layer compared with 27 for mass-spec protein and 7 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher PAPOLG mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated PAPOLG expression acts as an unfavorable survival marker, although some lineages such as LUAD and LSCC show a favorable association.

PDAC, LUAD, and CCRCC are the cancer types where PAPOLG mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	DFS	Quartile	All	0.284	0.606	.006	14	view →
LUAD	DFS	Median	II,III,IV	1.000	0.798	.015	8	view →
CCRCC	OS	Median	II,III,IV	0.805	1.000	.042	7	view →
LSCC	DFS	Quartile	All	0.962	0.866	.009	6	view →
HNSC	DFS	Median	All	0.560	0.755	.028	2	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

PAPOLG–PDAC (DFS)

Open the PDAC breakdown →